-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Benzinga·07/29/2026 17:43:14
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.